Biznes Fakty
Changes to the list of reimbursed medicines
As of Tuesday, twenty-nine new medications have been added to the reimbursement list. This includes treatments for hypertension, as well as medications for rare diseases and oncology therapies. Simultaneously, „Gazeta Wyborcza” reported in its Tuesday edition that the April reimbursement list lacked nearly 90 less expensive alternatives that received a favorable opinion from the Economic Commission.
The most recent reimbursement list features medications for managing hypertension: Iporel (clonidine) and Zofenil (zofenopril), along with Flecainide acetate Holsten (flecainide), which is utilized to address heart rhythm disorders.
The pharmacy will also provide the hypertension medication Tolutris (telmisartan + amlodipine + hydrochlorothiazide), covered for all registered indications, alongside Vabinxo (valsartan + indapamide) – also available for all registered indications.
Cystic fibrosis treatments, hepatitis C, and vaccines
Since April, reimbursement has included, among others, the anticipated therapy for patients aged two and older with cystic fibrosis who have at least one gene mutation – specifically, the drugs Kalydeco and Kaftrio.
The list also comprises medications used to treat hepatitis C in children: Epclusa (sofosbuvir + velpatasvir), Maviret (glecaprevir + pibrentasvir), Harvoni (sofosbuvir + ledipasvir), and Vosevi (sofosbuvir + velpatasvir + voxileprevir).
Since April , the Abrysvo vaccine for RSV has been covered for pregnant women and seniors aged 60 and above.
The Shingrix vaccine for shingles is reimbursed at 50% for individuals aged 18-65 who are at heightened risk of the disease, with full reimbursement for seniors.
Ultimately, it was announced by Deputy Health Minister Marek Kos in March that patients will have the opportunity to receive shingles vaccinations at pharmacies.
New cancer treatments
The April list introduces 10 new oncology treatments, including three for rare diseases. Additionally, there are 19 new drugs in non-oncology therapies, four of which are for rare diseases.
The newly covered oncology treatments include durvalumab and tremelimumab for first-line therapy of non-small cell lung cancer; alectinib for post-surgical treatment of lung cancer; abemaciclib for treating post-operative early HER-2 negative breast cancer; and rucaparib for ovarian, fallopian tube, and peritoneal cancer treatment.
Other medications added to the reimbursement list since April 1 include: elranatamab and talcvetamab for fourth-line treatment of multiple myeloma, talazoparib for castration-resistant prostate cancer in combination with enzalutamide, nivolumab for adjuvant melanoma treatment in patients aged 12 and older, as well as acalabrutinib for first-line treatment of chronic lymphocytic leukemia (expansion to include low-risk patients) and dostarlimab for first-line treatment of advanced or recurrent endometrial cancer.
Since April, the list has also incorporated Nucala (mepolizumab), a medication for adults diagnosed with hypereosinophilic syndrome (HES) and for patients aged six and older with eosinophilic granulomatosis (EGPA). Livtencity (maribavir) will be reimbursed for patients after hematopoietic stem cell or solid organ transplantation infected with CMV in second or subsequent lines of treatment. Amvuttra (wutrisiran) will be funded for treating hereditary transthyretin amyloidosis with polyneuropathy. Kinpeygo (budesonide) is also set to be reimbursed for adult patients with primary nephropathy.
The reimbursement list further includes bevacizumab (under various brand names) for treating patients with retinal vein occlusion BRVO (branch vein occlusion) and CRVO (central retinal vein occlusion).
Modifications to drug programs
Adjustments have also been made to drug programs. In program B.25, concerning treatment for patients with mucopolysaccharidosis type II (Hunter syndrome), the age limit for administering idursulfase has been removed. In program B.29, which addresses multiple sclerosis treatment, starting April 1, the qualification criteria for cladribine will be standardized, akin to other medications used in the first-line treatment of relapsing-remitting multiple sclerosis (RRMS).
In
Źródło
